FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Nootropic In Vitro Research Only

Semax: Neuroprotection, BDNF Elevation & Cognitive Performance Research

BDNF Increase — Hippocampus Within 24 Hours

Semax is a synthetic heptapeptide analogue of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia and approved for clinical use since 1991 for stroke treatment and cognitive impairment. Dolotov et al. demonstrated that a single intranasal dose produced 8-fold increases in BDNF protein in the hippocampus within 24 hours, persisting for 72 hours — positioning Semax as the most potent BDNF-elevating peptide studied to date in preclinical models.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧠

BDNF Surge (8× Baseline)

A single intranasal dose produces 8-fold hippocampal BDNF increases within 24 hours — the most potent BDNF-elevating effect documented for any single peptide in preclinical models.

🧬

NGF & VEGF Upregulation

Also increases Nerve Growth Factor and VEGF — promoting neuronal survival, new synapse formation, and vascular repair in the CNS.

⚗️

HIF-1α Ischaemia Protection

Activates Hypoxia-Inducible Factor-1α under ischaemic conditions, protecting neurons from oxygen deprivation — the mechanism behind its stroke recovery data.

🔬

Mesocortical Dopamine Enhancement

Enhances dopaminergic neurotransmission in the mesocortical pathway, contributing to pro-cognitive and focus-enhancing effects observed in both animal and human research.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

🧠
BDNF Elevation (24h)
Dolotov et al. (2006) J Neurochem
💊
1991
Clinical Use Since
Russia & Ukraine stroke protocols
⏱️
72h
BDNF Effect Duration
Single intranasal dose
👁️
+VA
Visual Acuity Improvement
Optic neuropathy human trial

Semax BDNF Protein Elevation — Time Course After Single Intranasal Dose

Baseline
1
6h
3
12h
6
24h
8
48h
5
72h
3

BDNF relative to baseline (fold-change). Source: Dolotov et al. (2006) J Neurochem. PMID 16899067. Rat hippocampus model.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

95%

Tolerability

Low Severity
10%

Mild Nasal Irritation

Low Severity
4%

Transient Headache

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.

RESEARCH CITATIONS

Primary literature — links open PubMed or original journal source

Syntra Compound Library

View SEMAX specifications, batch data, and Certificate of Analysis in the Syntra research compound catalogue.

View SEMAX in the Syntra Compound Library →

For in vitro laboratory research use only. Not for human consumption.

← Back to Peptide Research Library
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →